← Back to headlines
Analyst Raises Generate Biomedicines Price Target Following Positive Asthma Trial Results
H.C. Wainwright upgraded its price target for Generate Biomedicines to $30, citing promising clinical data related to the company's asthma treatment pipeline.
28 Aug, 11:56 — 28 Aug, 11:56
Sources
Showing 1 of 1 sources
Related Stories
Signet Jewelers Raises Profit Forecast After Strong Quarterly Results
46m ago
Nigeria’s Oil Regulator Threatens Permit Revocations for Idle Gas Flare Sites
1h ago
Record Travel Demand Hits Dublin Airport and Portuguese Cruise Industry
1h ago
Corporate Earnings Highlights from Wells Fargo and Goldman Sachs Conferences
1h ago